Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2020-07-02 Regulatory Filings
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from Propanc Biopharma, Inc. responding to comments from the SEC staff regarding a Preliminary Information Statement on Schedule 14C. The content focuses on clarifications about a reverse stock split, authorized shares, and fractional shares treatment. The document references Schedule 14C, which is used for information statements related to shareholder voting matters but is not the information statement itself. The letter is a regulatory correspondence addressing SEC comments and does not contain financial statements or the actual information statement. The document length is 3677 characters, which is relatively short and consistent with a regulatory filing or comment response rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a response to SEC comments on a filing and does not constitute the actual information statement or a proxy solicitation document itself.
2020-07-02 English
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is a correspondence letter from Propanc Biopharma, Inc. to the SEC staff regarding comments on a Registration Statement on Form S-1 filed by the company. The letter addresses SEC staff comments, clarifies the nature of the offering (secondary offering of outstanding shares by a selling stockholder), and discusses compliance with Securities Act rules. It also mentions an amendment to the registration statement and updates to financial statements for the quarter ended March 31, 2020. The document is a regulatory correspondence related to a securities registration filing, not a financial report, earnings release, or other report type. It is primarily a regulatory filing responding to SEC comments and does not contain financial statements or detailed financial analysis itself. Therefore, it fits best under Regulatory Filings (RNS).
2020-06-26 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC. It includes detailed information about the securities being registered for public offering, including common stock and warrants, pricing, and terms of the offering. The document is a registration statement under the Securities Act of 1933, which is used for initial public offerings or other securities offerings. It is not an annual report, earnings release, or any other type of financial report. It is also not a proxy statement, voting results, or management change announcement. The document is a capital raising filing related to the registration of securities for sale to the public. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or notice, so it is not a Report Publication Announcement or Regulatory Filing fallback. Confidence is high given the clear identification as an S-1 registration statement amendment related to securities offering.
2020-06-26 English
Regulatory Filings 2020
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, form names, fiscal period dates, or document titles that can be used to identify the filing type. The text is not a typical financial report or announcement and lacks any discernible structure or information. Given the absence of any identifiable information and the fallback rule for documents that do not fit into any specific category, the appropriate classification is Regulatory Filings (RNS).
2020-06-26 English
Proxy Solicitation & Information Statement 2020
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14C Information Statement filed with the SEC by Propanc Biopharma, Inc. It is titled as an "Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934" and relates to a corporate action taken by written consent of stockholders to approve a reverse stock split. The document explicitly states it is not a proxy solicitation or a notice of a meeting, but an information statement notifying stockholders of the action taken without a meeting. The content focuses on corporate governance actions, stockholder voting results, and amendments to the Certificate of Incorporation. This type of filing is a proxy solicitation or information statement to shareholders to inform them about corporate actions and solicit votes or consents, which aligns with the Proxy Solicitation & Information Statement (PSI) category. It is not an Annual Report, Earnings Release, or Management Report, nor is it a simple announcement or regulatory filing. The document length and detail confirm it is the statement itself, not just an announcement. Therefore, the correct classification is PSI with high confidence.
2020-06-11 English
Regulatory Filings 2020
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document as any specific filing type. According to the fallback rule, documents that do not fit any specific category should be classified as Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable.
2020-05-28 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.